The adjunctive use of anti-vascular endothelial growth factor agents in the management of iris neovascularisation in Malaysia

Mae-Lynn Catherine Bastion, K. Y. Then, H. A. Faridah, Mushawiahti Mustapha, Othmaliza Othman, H. S. Wong

Research output: Contribution to journalArticle

Abstract

This retrospective study investigated the role of antivascular endothelial growth factor agents (VEGF), ranibizumab, bevacizumab and pegaptanib sodium in patients with iris neovascularisation (INV), in which 9 eyes received intraocular injections for various ischaemic ocular conditions. Ocular sequelae included recurrence of rubeosis (n=2) and hyphaema (n=2). Systemic complication included one case of cerebrovascular accident. INV regressed in all cases from day one. INV recurrence occurred in 2 cases. The mean intraocular pressure of the study eyes decreased from 25.3 mmHg to 18.3 mmHg at one month. Five eyes are medication free. Visual acuity improved in 5 eyes. Four eyes achieved a Snellen visual acuity of 6/24 or better. We conclude that the use of intraocular anti-VEGF agents are safe and effective for inducing the regression of INV. Patients with multiple systemic risk factors should be counseled on stroke risk.

Original languageEnglish
Pages (from-to)10-14
Number of pages5
JournalMedical Journal of Malaysia
Volume66
Issue number1
Publication statusPublished - Mar 2011

Fingerprint

Malaysia
Iris
Vascular Endothelial Growth Factor A
Visual Acuity
Stroke
Endothelial Growth Factors
Intraocular Injections
Hyphema
Recurrence
Intraocular Pressure
Retrospective Studies

Keywords

  • Anti-vascular growth factor agents
  • Bevacizumab
  • Iris neovascularisation
  • Pegaptanib sodium
  • Ranibizumab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{c06cb01024434c449d6fed6114a89adf,
title = "The adjunctive use of anti-vascular endothelial growth factor agents in the management of iris neovascularisation in Malaysia",
abstract = "This retrospective study investigated the role of antivascular endothelial growth factor agents (VEGF), ranibizumab, bevacizumab and pegaptanib sodium in patients with iris neovascularisation (INV), in which 9 eyes received intraocular injections for various ischaemic ocular conditions. Ocular sequelae included recurrence of rubeosis (n=2) and hyphaema (n=2). Systemic complication included one case of cerebrovascular accident. INV regressed in all cases from day one. INV recurrence occurred in 2 cases. The mean intraocular pressure of the study eyes decreased from 25.3 mmHg to 18.3 mmHg at one month. Five eyes are medication free. Visual acuity improved in 5 eyes. Four eyes achieved a Snellen visual acuity of 6/24 or better. We conclude that the use of intraocular anti-VEGF agents are safe and effective for inducing the regression of INV. Patients with multiple systemic risk factors should be counseled on stroke risk.",
keywords = "Anti-vascular growth factor agents, Bevacizumab, Iris neovascularisation, Pegaptanib sodium, Ranibizumab",
author = "Bastion, {Mae-Lynn Catherine} and Then, {K. Y.} and Faridah, {H. A.} and Mushawiahti Mustapha and Othmaliza Othman and Wong, {H. S.}",
year = "2011",
month = "3",
language = "English",
volume = "66",
pages = "10--14",
journal = "Medical Journal of Malaysia",
issn = "0300-5283",
publisher = "Malaysian Medical Association",
number = "1",

}

TY - JOUR

T1 - The adjunctive use of anti-vascular endothelial growth factor agents in the management of iris neovascularisation in Malaysia

AU - Bastion, Mae-Lynn Catherine

AU - Then, K. Y.

AU - Faridah, H. A.

AU - Mustapha, Mushawiahti

AU - Othman, Othmaliza

AU - Wong, H. S.

PY - 2011/3

Y1 - 2011/3

N2 - This retrospective study investigated the role of antivascular endothelial growth factor agents (VEGF), ranibizumab, bevacizumab and pegaptanib sodium in patients with iris neovascularisation (INV), in which 9 eyes received intraocular injections for various ischaemic ocular conditions. Ocular sequelae included recurrence of rubeosis (n=2) and hyphaema (n=2). Systemic complication included one case of cerebrovascular accident. INV regressed in all cases from day one. INV recurrence occurred in 2 cases. The mean intraocular pressure of the study eyes decreased from 25.3 mmHg to 18.3 mmHg at one month. Five eyes are medication free. Visual acuity improved in 5 eyes. Four eyes achieved a Snellen visual acuity of 6/24 or better. We conclude that the use of intraocular anti-VEGF agents are safe and effective for inducing the regression of INV. Patients with multiple systemic risk factors should be counseled on stroke risk.

AB - This retrospective study investigated the role of antivascular endothelial growth factor agents (VEGF), ranibizumab, bevacizumab and pegaptanib sodium in patients with iris neovascularisation (INV), in which 9 eyes received intraocular injections for various ischaemic ocular conditions. Ocular sequelae included recurrence of rubeosis (n=2) and hyphaema (n=2). Systemic complication included one case of cerebrovascular accident. INV regressed in all cases from day one. INV recurrence occurred in 2 cases. The mean intraocular pressure of the study eyes decreased from 25.3 mmHg to 18.3 mmHg at one month. Five eyes are medication free. Visual acuity improved in 5 eyes. Four eyes achieved a Snellen visual acuity of 6/24 or better. We conclude that the use of intraocular anti-VEGF agents are safe and effective for inducing the regression of INV. Patients with multiple systemic risk factors should be counseled on stroke risk.

KW - Anti-vascular growth factor agents

KW - Bevacizumab

KW - Iris neovascularisation

KW - Pegaptanib sodium

KW - Ranibizumab

UR - http://www.scopus.com/inward/record.url?scp=79960196214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960196214&partnerID=8YFLogxK

M3 - Article

VL - 66

SP - 10

EP - 14

JO - Medical Journal of Malaysia

JF - Medical Journal of Malaysia

SN - 0300-5283

IS - 1

ER -